Clinical Trials Browser

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT00107289 2026-03-13

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Phase 2 Recruiting

200 enrolled

CNSEndocrine

Neuroblastoma, Pheochromocytoma

NCT06427798 2026-03-10

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Phase 1/2 Recruiting

66 enrolled

CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05636540 2026-02-27

In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma

Phase EARLY_PHASE1 Recruiting

30 enrolled

CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT04924075 2026-02-24

MK-6482-015

Phase 2 Recruiting

322 enrolled 1 FDA

CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT03206060 2026-02-17

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Phase 2 Recruiting

130 enrolled

CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT06479811 2025-11-25

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Phase 1 Recruiting

120 enrolled

CNSEndocrineGenitourinaryHead & Neck

Head and Neck Neoplasms, Kidney Neoplasms, Paraganglioma, Pheochromocytoma

NCT05636618 2025-11-24

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

Phase 1/2 Recruiting

260 enrolled

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT06503146 2025-11-12

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Phase 2 Recruiting

320 enrolled

CNSEndocrineGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT07167329 2025-09-11

BELIEVE-VHL

Phase 2 Recruiting

100 enrolled

CNSEndocrineGenitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

NCT06683846 2025-08-24

Ivonescimab in the Treatment of Multiple Advanced Tumors

Phase 2 Recruiting

400 enrolled

CNSDermatologicEndocrineGenitourinarySarcoma

Urachal cancer, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Transitional Cell, Kidney Neoplasms, Paget Disease, Extramammary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Prostatic Neoplasms, Rhabdomyosarcoma, Sarcoma, Angiomyolipoma, Carcinoma, Neuroendocrine, Perivascular Epithelioid Cell Neoplasms

NCT06377033 2025-07-20

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

Phase NA Recruiting

1,000 enrolled

CNSEndocrine

Alzheimer Disease, Paraganglioma, Parkinson Disease, Pheochromocytoma, Polyneuropathies, Aortic Aneurysm, Thoracic, Genetic Predisposition to Disease, Frontotemporal Dementia

NCT06041516 2025-07-11

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

Phase 1 Recruiting

70 enrolled

CNSEndocrineNET

Neuroblastoma, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05702944 2025-06-12

The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma

Phase 4 Recruiting

24 enrolled

CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05944237 2025-06-08

HTL0039732 in Participants With Advanced Solid Tumours

Phase 1/2 Recruiting

150 enrolled

EndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06607692 2024-10-21